Article Information
History
- August 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Rujipas Sirijatuphat1,¶,
- Amorn Leelarasamee1,2,*,
- Thanapat Puangpet3,¶ and
- Arunee Thitithanyanont4,¶
- 1Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Thanon Wang Lang, Siriraj, Bangkoknoi, Bangkok 10700, Thailand
- 2Faculty of Medicine, Siam University, 38 Petchkasem Rd, Bang Wa, Phasi Charoen, Bangkok 10160, Thailand
- 3Samut Sakhon Hospital, 1500 Ekkachai Rd, Tambon Mahachai, Mueang Samut Sakhon District, Samut Sakhon 74000, Thailand
- 4Department of Microbiology, Faculty of Science, Mahidol University, 272 Rama VI Road, Ratchathewi District, Bangkok 10400, Thailand
- ↵*Corresponding author:
E-mail: amorn.lee{at}mahidol.ac.th (AL)
↵¶ These authors contributed equally to this work.
Posted August 22, 2022.
A pilot study of 0.4% povidone-iodine nasal spray to eradicate SARS-CoV-2 in the nasopharynx
